OXAID: Oxygenating Hydrogel for Diabetic Wound Care
Award amount
$224,977Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- O2 REGENTECH LLC
- Proposal award date
- 2016-09-06
- Contract end date
- 2019-08-31
- UEI
- Y27TXM697LZ6
- Solicitation number
- PA14-054
- Topic code
- 200
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
2 SBIR/STTR records share this UEI (2016–2017). Reported award amounts total $449,977. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation